Lipocine Inc (LPCN)
6.92
-0.01
(-0.14%)
USD |
NASDAQ |
May 31, 16:00
6.92
0.00 (0.00%)
After-Hours: 20:00
Lipocine Enterprise Value: 12.38M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 12.38M |
| May 30, 2024 | 12.43M |
| May 29, 2024 | 10.61M |
| May 28, 2024 | 10.82M |
| May 24, 2024 | 12.22M |
| May 23, 2024 | 10.34M |
| May 22, 2024 | 10.66M |
| May 21, 2024 | 10.50M |
| May 20, 2024 | 9.434M |
| May 17, 2024 | 7.669M |
| May 16, 2024 | 6.118M |
| May 15, 2024 | 5.423M |
| May 14, 2024 | 3.979M |
| May 13, 2024 | 3.605M |
| May 10, 2024 | 3.819M |
| May 09, 2024 | 3.391M |
| May 08, 2024 | 1.305M |
| May 07, 2024 | 2.161M |
| May 06, 2024 | 1.680M |
| May 03, 2024 | 0.3962M |
| May 02, 2024 | 0.5031M |
| May 01, 2024 | 0.5566M |
| April 30, 2024 | 0.0753M |
| April 29, 2024 | 0.6636M |
| April 26, 2024 | 1.026M |
| Date | Value |
|---|---|
| April 25, 2024 | -0.2991M |
| April 24, 2024 | -0.8873M |
| April 23, 2024 | 1.038M |
| April 22, 2024 | 2.482M |
| April 19, 2024 | 3.551M |
| April 18, 2024 | 4.461M |
| April 17, 2024 | 3.819M |
| April 16, 2024 | 0.824M |
| April 15, 2024 | 4.006M |
| April 12, 2024 | 6.253M |
| April 11, 2024 | 9.442M |
| April 10, 2024 | 9.974M |
| April 09, 2024 | 6.040M |
| April 08, 2024 | 3.329M |
| April 05, 2024 | 0.8838M |
| April 04, 2024 | -0.1262M |
| April 03, 2024 | 1.575M |
| April 02, 2024 | 1.788M |
| April 01, 2024 | 3.542M |
| March 31, 2024 | 3.010M |
| March 28, 2024 | 5.607M |
| March 27, 2024 | 5.228M |
| March 26, 2024 | 4.597M |
| March 25, 2024 | 1.354M |
| March 22, 2024 | -0.5597M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-11.30M
Minimum
Oct 30 2023
171.08M
Maximum
Feb 10 2021
38.54M
Average
32.74M
Median
Enterprise Value Benchmarks
| Alpine Immune Sciences Inc (DELISTED) | 4.151B |
| Eliem Therapeutics Inc | 115.77M |
| NovaBay Pharmaceuticals Inc | 4.387M |
| Palatin Technologies Inc | 19.03M |
| iBio Inc | 28.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.514M |
| Revenue (Quarterly) | 7.617M |
| Total Expenses (Quarterly) | 4.395M |
| EPS Diluted (Quarterly) | 0.66 |
| Profit Margin (Quarterly) | 46.13% |
| Earnings Yield | -24.71% |
| Normalized Earnings Yield | -24.91 |